Panera Bread Company (NASDAQ: PNRA), MannKind Co. (NASDAQ: MNKD), MSC Industrial Direct Co., Inc. (NYSE: MSM), Petsmart Inc (NASDAQ: PETM), Polaris Industries Inc (NYSE: PII) and Pall Co. (NYSE: PLL) upgraded by analysts.
MannKind Co. (MNKD) was upgraded by JMP Securities from a “Market Perform” rating to an “Outperform” rating. They have a price target of $7.00 on the company.
MSC Industrial Direct Co., Inc. (MSM) was upgraded by BB&T (NYSE:BBT) from a “Hold” rating to a “Buy” rating.
Petsmart Inc. (PETM) was upgraded by Oppenheimer from a “Perform” rating to an “Outperform” rating. They have a price target of $49.00 on the company.
Polaris Industries Inc. (PII) was upgraded by Wells Fargo & Co. (NYSE:WFC) from a “Market Perform” rating to an “Outperform” rating.
Pall Co. (PLL) was upgraded by Wedbush from a “Neutral” rating to an “Outperform” rating. They have a price target of $60.00 on the company.
Panera Bread Company (PNRA) was upgraded by Miller Tabak from a “Hold” rating to a “Buy” rating. They have a price target of $125.00 on the company, up from $118.00.
Showing posts with label MannKind. Show all posts
Showing posts with label MannKind. Show all posts
Monday, August 15, 2011
Wednesday, May 11, 2011
Ratings on (HMIN) (MHR) (MNKD) (MOBI) (MXIM) Reiterated
Ratings on Home Inns & Hotels Management Inc. (NASDAQ: HMIN), Magnum Hunter (NYSE: MHR), MannKind Co. (NASDAQ: MNKD), Sky-mobi (NASDAQ: MOBI) and Maxim Integrated Products Inc. (NASDAQ: MXIM) reiterated by analysts.
Goldman Sachs (NYSE:GS) reiterated a “neutral” rating on Home Inns & Hotels Management Inc. (HMIN).
Wunderlich reiterated a “buy” rating on Magnum Hunter (MHR). They have a price target of $9.20 on the company.
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “underweight” rating on MannKind Co. (MNKD).
Citigroup (NYSE:C) reiterated a “buy” rating on Sky-mobi (MOBI). They have a price target of $23.00 on the company.
Citigroup reiterated a “buy” rating on Maxim Integrated Products Inc. (MXIM). They have a price target of $35.00 on the company.
Goldman Sachs (NYSE:GS) reiterated a “neutral” rating on Home Inns & Hotels Management Inc. (HMIN).
Wunderlich reiterated a “buy” rating on Magnum Hunter (MHR). They have a price target of $9.20 on the company.
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “underweight” rating on MannKind Co. (MNKD).
Citigroup (NYSE:C) reiterated a “buy” rating on Sky-mobi (MOBI). They have a price target of $23.00 on the company.
Citigroup reiterated a “buy” rating on Maxim Integrated Products Inc. (MXIM). They have a price target of $35.00 on the company.
Thursday, January 20, 2011
Mannkind (NASDAQ:MNKD) Shares Crushed on Request for Additional Trials of Afrezza
Mannkind (NASDAQ:MNKD) shares are getting hammered today on the news the FDA has requested more trials for Afrezza.
"The principal issue raised by the FDA concerned the usage of in vitro performance data and clinical pharmacology data to bridge MannKind’s next-generation inhaler to the phase 3 trials conducted using its MedTone inhaler," said Mannkind in a statement.
Mannkind CEO Alfred Mann added, "We plan to meet with the agency as quickly as possible in order to be confident that these trials, with appropriate modifications to incorporate a comparison to the MedTone device, will suffice in addressing the agency's questions about patient use and robustness of the next-generation device."
The MedTone inhaler is a next-generation inhaler requlators said the company must use in trials to generate more data on how it performs and is used, as well as how its handled and stored.
MannKind was trading at $5.36, down $3.75, or 41.16 percent, as of 11:06 AM EST.
"The principal issue raised by the FDA concerned the usage of in vitro performance data and clinical pharmacology data to bridge MannKind’s next-generation inhaler to the phase 3 trials conducted using its MedTone inhaler," said Mannkind in a statement.
Mannkind CEO Alfred Mann added, "We plan to meet with the agency as quickly as possible in order to be confident that these trials, with appropriate modifications to incorporate a comparison to the MedTone device, will suffice in addressing the agency's questions about patient use and robustness of the next-generation device."
The MedTone inhaler is a next-generation inhaler requlators said the company must use in trials to generate more data on how it performs and is used, as well as how its handled and stored.
MannKind was trading at $5.36, down $3.75, or 41.16 percent, as of 11:06 AM EST.
Wednesday, December 29, 2010
MannKind's (NASDAQ:MNKD) Afrezza FDA Delay a Neutral Event
MannKind (NASDAQ:MNKD) would have liked to have had the FDA give them a positive decision concerning Afrezza, but Wells Fargo (NYSE:WFC), while acknowledging it could cause problems if the delay is for a long period of time, considers it a neutral event over the short term.
Wells said, "We maintain our rating on the potential for Afrezza. Though a positive decision would have been preferred, we think a short delay by the FDA is better than a complete response letter (CRL) and should be viewed as a generally neutral outcome. Additional approval delays could become problematic but we think MNKD should be able to fund operations through 2011 with cash and credit currently available."
Wells Fargo maintains an "Outperform" rating on MannKind, which closed Tuesday at $8.23, gaining $0.26, or 3.26 percent. Wells has a price target range of $11 to $13 on them.
Wells said, "We maintain our rating on the potential for Afrezza. Though a positive decision would have been preferred, we think a short delay by the FDA is better than a complete response letter (CRL) and should be viewed as a generally neutral outcome. Additional approval delays could become problematic but we think MNKD should be able to fund operations through 2011 with cash and credit currently available."
Wells Fargo maintains an "Outperform" rating on MannKind, which closed Tuesday at $8.23, gaining $0.26, or 3.26 percent. Wells has a price target range of $11 to $13 on them.
Subscribe to:
Posts (Atom)